Skip to main content
LTRN
NASDAQ Life Sciences

Lantern Pharma Closes $4M Registered Direct Offering with Warrants

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$1.01
Mkt Cap
$12.912M
52W Low
$0.97
52W High
$4.703
52W Position info
4.1% above low
Off High info
79% below high
Rel. Volume info
2.4× avg
Market data snapshot near publication time

LTRN is trading near its 52-week low of $0.97 (4.1% above the low) on elevated volume (2.4× avg).

Summary

Lantern Pharma closed a $4M registered direct offering at $1.09/share with pre-funded and purchase warrants, adding placement agent fees and stockholder approval requirements.


Key Events · Financing and Capital Events · LTRN

  • Offering Closed

    Closed $4M registered direct offering on September 30, 2026: 1,469,725 common shares at $1.09 plus 2,200,000 pre-funded warrants at $1.0899.

  • Warrant Overhang

    Issued 3,669,725 purchase warrants at $1.09 exercise price in concurrent private placement, exercisable only after stockholder approval, expiring 5 years post-approval.

  • Placement Agent Terms

    Rodman & Renshaw received 7% cash fee, 5% warrant coverage (exercise price $1.3625), and 3% fee on future warrant exercises.

  • Stockholder Approval Required

    Company must seek stockholder approval within 90 days for warrant share issuance; if not obtained, must call meetings every 90 days until approval or warrants expire.


Analysis · LTRN · Life Sciences

Lantern Pharma closed a $4 million registered direct offering at $1.09 per share, issuing 1,469,725 common shares and 2,200,000 pre-funded warrants, plus 3,669,725 purchase warrants in a concurrent private placement. The deal adds material new terms: Rodman & Renshaw received a 7% cash fee, 5% warrant coverage, and a 3% fee on future warrant exercises. The company must seek stockholder approval within 90 days to allow warrant exercise, and file a resale registration statement within 30 days. Against a backdrop of a going-concern warning from the Q2 10-Q and a stock trading near its 52-week low, this capital raise provides runway but carries significant potential dilution if all warrants are exercised.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LTRN was trading at $1.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.9M. The 52-week trading range was $0.97 to $4.70. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LTRN - Latest Insights

LTRN
Nov 18, 2026, 8:00 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $0.3724
Real-time Price: $0.230 info
Change: -$0.1424 (-38%) info
Market Cap: $3.892M info
LTRN
Nov 18, 2026, 7:35 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.3724
Real-time Price: $0.230 info
Change: -$0.1424 (-38%) info
Market Cap: $3.892M info
LTRN
Nov 17, 2026, 4:25 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.365
Real-time Price: $0.230 info
Change: -$0.135 (-37%) info
Market Cap: $3.892M info
LTRN
Oct 08, 2026, 4:05 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $0.830
Real-time Price: $0.230 info
Change: -$0.600 (-72%) info
Market Cap: $3.892M info
LTRN
Oct 07, 2026, 8:31 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $0.950
Real-time Price: $0.230 info
Change: -$0.720 (-76%) info
Market Cap: $3.892M info